Introduction
Inherited retinal degenerations (IRDs) represent a diverse group of progressive, visually debilitating diseases that can lead to blindness in which mutations in genes that are critical to retinal function lead to progressive photoreceptor cell death and associated vision loss. IRDs are genetically heterogeneous, with over 260 disease genes identified to date. 1 The development of treatments and cures to modify the rate of disease progression has been limited to date, with some success of neurotrophic factor therapy and gene therapies reported from clinical trials. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The best example of treatment success is gene augmentation therapy for IRD caused by mutations in the RPE65 gene, which recently received US Food and Drug Administration (FDA) approval, which in fact represented the first FDA-approved gene therapy (GT) for any genetically inherited disease. [4] [5] [6] [7] [8] [9] Recent developments in the IRD field have advanced understanding of the mechanisms responsible for vision loss, creating new opportunities to intervene in the course of disease by developing new therapeutic approaches. In 2013, a Delphi-style gathering of IRD experts led to the identification, by consensus, of top priorities to advance therapeutic efforts for IRDs, including the need for systematic genotyping, improved standardization of visual function testing, development of more rigorous and widespread data collection protocols, and increased data sharing. 12 This document summarizes more recent advances in the IRD field and outlines specific knowledge gaps. These knowledge gaps present oppor-tunities for further investigation to enable development of therapies that may slow down or prevent vision loss, or restore vision, in affected patients.
Atrophic age-related macular degeneration (AMD) is included among the target inherited retinal diseases of interest because first, understanding AMD may contribute to understanding of inherited macular diseases, and second, understanding of the genetics and mechanism of inherited macular degenerations may contribute to understanding of AMD.
Recent Advances in IRD Research
The development of treatments for IRDs requires basic and translational research that leads to improved understanding of the nature and causes of these diseases. Brief summaries of recent advances in IRD research are included here.
Genetic Causes of Disease
Notable progress has been made identifying the genetic causes of IRDs, with over 260 disease genes identified to date. 1 By sequencing the coding regions of these disease genes via panel based genetic testing, it is currently possible to identify the genetic cause of disease for approximately two thirds of patients with IRDs [13] [14] [15] and up to 85% of children with IRDs. 16 Additional mutations can be identified using whole genome sequencing. 17 Active research programs in multiple centers are directed toward identifying the genetic causes of disease in the one third of patients who do not have identifiable mutations in the presently known IRD disease genes. This includes discovery of additional novel disease genes, and identification of noncoding mutations, including structural variants (SVs) in the genome. 18 Additionally, the identification and characterization of modifier genes, which themselves do not cause disease but ''modify'' the disease severity caused by other disease causing mutations is in its infancy, but has great potential for identifying new targets and approaches for treatment. Lastly, it may be worthwhile to evaluate patients with unilateral disease for somatic mutations 19, 20 or other potential causes of retinal degeneration such as posterior uveitis, 21 acute zonal occult outer retinopathy, 22 or medication toxicity.
23,24
Disease Pathogenesis
Identification of the genetic causes of IRDs has led to improvements in our understanding of retinal biology in general, and in some cases to our understanding of disease pathogenesis. For example, several cell death mechanisms including apoptosis and necrosis have been shown to be activated in different genetic forms of IRD. 25, 26 Delineation of the genetic causes of syndromic ciliopathies has led to improved understanding of photoreceptor cell structure, and the importance of cellular transport processes such as intraflagellar transport in IRDs. 27, 28 Studies of the noncell autonomous nature of cone cell death in rodcone degenerations has led to recognition of metabolic and oxidative stress in photoreceptor dysfunction and death. 29, 30 These studies have also identified supportive factors such as RdCVF and NRF2 that could be used to develop nongene specific treatments that may be beneficial to groups of disorders that are caused by mutations in a variety of different genes and that could potentially also help at later stages of the disease process.
Technical advances in the modeling of disease have facilitated improved understanding of pathophysiology and basic mechanisms of IRDs to identify novel targets for therapy and provide proof of concept for therapeutic strategies. The use of induced pluripotent stem cells (iPSCs) to model disease has provided a platform to study IRDs that do not have a relevant animal model or for which the human mutations have not been recapitulated in an animal model. 31 Further, iPSC models have proven useful in establishing proofof-concept when an animal model is absent. For example, the use of iPSC to validate gene augmentation as a therapeutic strategy for choroideremia has resulted in FDA approval of a phase I/II clinical trial (NCT02341807). 32 
Disease Progression
Consensus guidelines for the care of patients with IRDs can be viewed at the American Academy of Ophthalmology Clinical Education Guidelines portal. 33 Recent developments that have advanced the retinal degenerations field in clinical structure and function have related to novel technologies that enables improved assessment of retinal structure and function. Optical coherence tomography (OCT) provides noninvasive, objective assessment of retinal structure. The axial resolution is 5 lm with commercially available OCT systems, 34 and the outer retinal layers including the outer nuclear layer, the external limiting membrane, the inner segments, the inner segment/outer segment junction or ellipsoid zone (EZ), the outer segments, and the retinal pigment epithelium (RPE) can be measured in eyes with IRD. Numerous studies have established a relationship between visual field parameters and structure on OCT. [35] [36] [37] [38] [39] [40] The objective, quantitative, and highresolution nature of OCT measures combined with correlation to functional measures has created interest in using the EZ area as a potential clinical trial outcome measure. 41 In addition, swept-source OCT penetrates deeper into the choroid to facilitate optical coherence tomography angiography (OCTA), 42 which may provide insight into how retinal and choroidal vasculature is affected in eyes with different forms of retinal degeneration. Choroidal abnormalities may play a role in disease pathogenesis in conditions like choroideremia and gyrate atrophy, and may be a target for potential drug delivery.
Since photoreceptors degenerate in IRDs with consequent visual loss, imaging photoreceptors in living eyes noninvasively could provide insight into rod and cone structure during disease progression and in response to experimental therapies. However, most clinical imaging modalities do not have adequate resolution to visualize individual photoreceptors at the cellular level. Adaptive optics is a strategy to measure aberrations in light exiting the eye that reduce image resolution and prevent images of photoreceptors at the cellular level. 34, [43] [44] [45] Adaptive optics scanning laser ophthalmoscopy (AOSLO) captures confocal light wave-guided by photoreceptors with intact inner and outer segments, 44, 46, 47 while split-detector AOSLO images nonconfocally wave-guided light, to visualize cones with only inner segments. [48] [49] [50] [51] [52] [53] [54] [55] Split detector systems can also be used to see inner retinal structures 56 and RPE cells using dark field imaging. 57 Adaptive optics systems are not widely available but are valuable research tools to improve understanding of photoreceptor survival in eyes with IRD, and may have potential as a sensitive, objective outcome measure of safety and efficacy in clinical trials for IRD patients. 58 Continuing a long history of studies of the course of disease for specific IRDs, [59] [60] [61] [62] [63] [64] [65] [66] [67] 75 My Retina Trackert, now the largest patient-driven registry in the IRD community, continues to amass genetic data that is accessible to researchers globally. 75 
Neuroprotective Agents
Therapies that may slow photoreceptor degeneration due to a range of genetic causes have also been investigated. Vitamin A and docosahexaenoic acid have been demonstrated to provide modest reductions in the rate of disease progression in patients with retinitis pigmentosa (RP). 2, 3, [76] [77] [78] [79] [80] [81] [82] Oral valproic acid was reported to slow visual field progression in a case series of RP patients, 83 but a randomized clinical trial of valproic acid treatment in patients with autosomal dominant RP showed no significant difference between patients treated with valproic acid and placebo (https://www.clinicaltrials.gov/ct2/show/results/ NCT01233609?term=01233609&rank=1&sect= X01256#all).
Advances in high-throughput screening have accelerated the pace of identifying cellular targets and candidate neuroprotective agents. Oxidative damage has been implicated in photoreceptor degeneration, 84 and N-acetylcysteine (NAC) 85 and N-acetylcysteine amide (NACA) 86 have been shown to prevent retinal degeneration in preclinical studies of RP. A clinical trial of NAC in RP patients is in progress (NCT0306302). Nonspecific neurotrophic factor therapy with ciliary neurotrophic factor (CNTF) has been shown to slow photoreceptor degeneration in a number of animal models, but did not demonstrate visual function benefit in human clinical trials of patients with early or advanced RP. 87 However, neurotrophic factors that reduce photoreceptor susceptibility to oxidative stress and promote cone outer segment regeneration, such as rod-derived cone viability factor (RdCVF) show promise in preserving cone photoreceptors in eyes with RP in preclinical models, 88 and clinical trials are planned in patients with RP. Various protein kinase inhibitors have also been shown to slow retinal degeneration in various mouse and rat models of IRD.
Gene and Genetic (Gene-Specific) Therapies
Based on progress in understanding the genetic causes of IRDs, significant effort has been directed toward developing gene augmentation therapies for specific genetic forms of IRD. Reports of success of clinical trials of gene augmentation therapy for RPE65-and CHM-associated retinal degeneration suggest the great potential of gene therapies for the treatment of IRDs. 10, 89, 90 The recent FDA approval of gene augmentation therapy for RPE65-associated IRD is an important milestone and suggests that similar approaches can be used for the treatment of many other genetic forms of IRD. For example, preclinical studies support the broad use of gene therapies for the treatment of IRDs, with proof-ofconcept of benefit reported in at least 24 genetic forms of disease. Genome editing, including CRISPR-based therapies, and genetically directed pharmacologic therapies, including antisense oligonucleotides, premature termination codon readthrough strategies, base editing, and RNA editing are also promising approaches for genetic forms of disease that may be not amenable to gene augmentation therapies. 84, 112, [114] [115] [116] [117] [118] [119] [120] Regenerative Medicine
Building on data from studies of retinal development, there is now great interest in the use of retinal stem cells for the study and treatment of IRDs. Recent studies show that instead of or in addition to integration of donor cells into the host retina, transplanted photoreceptor precursors into animal models of retinal degenerative disease demonstrated transfer of cytoplasmic material from donor to recipient photoreceptors. 59, [121] [122] [123] [124] [125] [126] Transplanted donor cell integration and material transfer between transplanted and host cells may both underlie the therapeutic benefits associated with transplantation therapy. It may also be possible to take advantage of material transfer between cells for therapeutic purposes, such as stimulation of host Müller cells to differentiate into photoreceptor cells. 127 Another approach to transplantation involves iPSC-derived organoids, which enhances the possibility of autologous transplants. 128, 129 Retina organoids can be used for disease modeling, as well as for therapeutic purposes. 130, 131 There are many efforts underway to develop in vitro models of degenerative retinal disease, which will enable high throughput screening of possible therapies, as well as facilitate understanding of disease mechanisms. The National Eye Institute announced the 3-D retina organoid challenge (https://www.nih.gov/news-events/newsreleases/nih-solicits-next-generation-retina-organoidsprize-competition). Erin Lavik, Sc.D., won the ''ideation phase'' of this competition. Lavik's team proposed using a method to screen print tissue models. Her group will create layers of the various types of retinal neurons that can be derived in a lab from adult stem cells. The method would allow the layers to be correctly oriented to mimic the structure of the human retina.
Approximately 20 early phase clinical trials (www. clinicaltrials.gov) involving cell-based therapy for degenerative retinal disease are underway. Therapeutic targets include the advanced atrophic form of AMD, 132 choroidal neovascularization associated with AMD, Stargardt disease, RP, and atrophy associated with high myopia. Therapeutic cells under study in these trials include autologous bone marrowderived stem cells, human retinal progenitor cells, embryonic stem cell-derived RPE, iPSC-derived RPE, and human CNS stem cells. 133 As a note of caution, there is evidence of severe visual loss including complete blindness after ocular injection of autologous adipose derived ''stem cells'' from unregulated clinics in the United States. 134 There were no clinical trials that supported these treatments and, thus, it remains of utmost importance to wait for the results of formal clinical trials that test the safety and efficacy of these emerging new treatments before patients should undergo any such treatment in a clinical setting.
Visual Prosthetics
For patients with IRD there have traditionally been no effective treatments to restore vision. In 2013, an epiretinal prosthetic device received human use device (HUD) exemption from the FDA for use in patients with near total vision loss due to RP. Since then, over 200 patients world-wide have received the Argus 2e device from Second Sight Medical Products, Inc. (Sylmar, CA) with some evidence of improved visual function and performance. [135] [136] [137] [138] [139] Other retinal prostheses that target various regions of the visual pathway are under development or are in clinical trials including the electronic retinal implant Alpha AMS, 140, 141 Intelligent Retinal Implant System (IRIS V2 (NCT02670980), Suprachoroidal Retinal Prosthesis (NCT01603576), and the PRIMA high-resolution photovoltaic retinal prosthetic system (NCT03333954).
Optogenetics provides the opportunity to confer novel light-sensing properties to inner retinal neurons that normally have nonimage forming light sensitivity such as bipolar cells and retinal ganglion cells. The strategy involves transfecting inner retinal neurons with a gene encoding a light-sensitive protein such as channelrhodoposin-2 or halorhodopsin. Optogenetic proteins can be sensitive to wavelengths of natural light (Allergan RST-001, NCT02556736) or genetically red-shifted to decrease the potential for light damage by bright white light. In this case, an external visual interface (goggles) transforms external light stimuli into signal that activates the transduced retinal ganglion cells with the appropriate (infrared) wavelength (GenSight Biologics GS030, NCT03326336; GenSight Biologics SA, Paris, France).
This combination of GT and electronics could offer cell specificity, as well as stimulation of a large number of neurons via viral vector-based transfection technology, delivered by intravitreal injection. The light-sensing receptors may also be built into actual artificial retina implants. 142, 143 Specific Knowledge Gaps That Should Be Addressed to Advance the Field
The goal of this analysis of gaps in knowledge regarding IRDs is to identify priority areas for research that will accelerate progress toward development of treatments and cures for IRDs.
Genetics of IRDs (GE)
The goals of this Research Priority Area include: Many times, the phenotype of a condition can be ambiguous and molecular genetic diagnosis leads to the accurate clinical diagnosis. A genetic diagnosis can identify potential treatment options for patients, inform them about the potential risk of disease to family members, and identify the potential risk that other organ systems may be affected in syndromic diseases. An important goal in the IRD field is for molecular genetic diagnostic testing to become a routine part of clinical care, and for testing to be accessible, affordable, and accurate. 12 A related goal is to improve the sensitivity of testing such that pathogenic or likely pathogenic mutations causing IRDs are identified in a substantial fraction of cases (at least 95%).
Specific Knowledge Gaps 1. Identify the remaining ''elusive'' genetic causality of IRDs a. Identify remaining IRD disease genes b. Identify noncoding mutations in IRD disease genes
As described above, the genetic cause of disease can be found for approximately two thirds of patients via sequencing of the coding regions of known IRD disease genes. The genetic causality for the remaining one third of patients needs to be identified. Based on results of ongoing studies by multiple research groups, it is apparent that the genetic causes of disease in these patients and families will be distributed between novel IRD disease genes and noncoding mutations, including SVs in known disease genes.
Incorporate improved sequencing methods into
research and diagnostic testing, including longread sequencing, single-molecule sequencing, advanced methods to detect copy number variants (CNVs) and other types of SVs, and methods to reconstruct extended haplotypes. 3. Improve the ability to determine which rare variants are damaging, potentially pathogenic, and likely disease-causing to resolve variants of uncertain significance (VUSs), using bioinformatics and computational approaches, collaborative data sharing, and functional assays, including in vitro, cell, and animal based assays. 
Cell and Molecular Mechanisms of Retinal Disease (CMM)
The goals of this Research Priority Area include:
1. Improve our understanding of the mechanisms by which mutations in IRD disease genes cause dysfunction and death of retinal cells so that improved therapies to prevent vision loss can be developed. 2. Delineate pathways that link mutations in multiple different genes to common disease mechanisms and molecular pathways, with the goal of identifying potentially common therapeutic targets that are applicable to groups of genetic forms of IRD. 3. Determine mechanisms and pathways by which modifier genes and environmental factors modulate the disease impact of IRD-causing mutations, since such understanding could also identify new targets and pathways for therapeutic intervention.
Specific Knowledge Gaps 
Clinical-Structure and Function (CL)
The goals of this Research Priority Area include: Gene Therapy (GT) Addressing the knowledge gap detailed above will likely require projects that incorporate components of multiple project areas because the gaps are synergistic. Making progress to address the gaps will require multipronged, multidisciplinary approaches. Many of the gaps listed pertain to more sections than the ones listed above, and impactful research projects will address gaps and problems from multiple different approaches.
